Status:
COMPLETED
Study Evaluating Pharmacovigilance Of Refacto AF
Lead Sponsor:
Pfizer
Conditions:
Hemophilia A
Eligibility:
All Genders
Brief Summary
The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.
Detailed Description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Eligibility Criteria
Inclusion
- Patients with hemophilia A of any severity already receiving or starting treatment with ReFacto AF.
Exclusion
- Patients with Hemophilia A treated with a product other than Refacto AF.
Key Trial Info
Start Date :
July 17 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 19 2016
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT00895037
Start Date
July 17 2009
End Date
October 19 2016
Last Update
July 17 2018
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
LKH - Univ. Klinikum Graz,Abt. fur Hamatologie
Graz, Austria, 8036
2
Allgemeines Krankenhaus Linz, Kinderklinik
Linz, Austria, 4020
3
Universitaetsklinik fuer Innere Medizin 1
Vienna, Austria, 1090
4
Sonnengesundheitszentrum
München, Bavaria, Germany, 80336